Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;13(11):1139-1151.
doi: 10.1016/S1474-4422(14)70137-1.

Controversies in HIV-associated neurocognitive disorders

Sam Nightingale  1 , Alan Winston  2 , Scott Letendre  3 , Benedict D Michael  4 , Justin C McArthur  5 , Saye Khoo  6 , Tom Solomon  4
Affiliations
Review

Controversies in HIV-associated neurocognitive disorders

Sam Nightingale et al. Lancet Neurol. 2014 Nov.

Abstract

Cross-sectional studies show that around half of individuals infected with HIV-1 have some degree of cognitive impairment despite the use of antiretroviral drugs. However, prevalence estimates vary depending on the population and methods used to assess cognitive impairment. Whether asymptomatic patients would benefit from routine screening for cognitive difficulties is unclear and the appropriate screening method and subsequent management is the subject of debate. In some patients, HIV-1 RNA can be found at higher concentrations in CSF than in blood, which potentially results from the poor distribution of antiretroviral drugs into the CNS. However, the clinical relevance of so-called CSF viral escape is not well understood. The extent to which antiretroviral drug distribution and toxicity in the CNS affect clinical decision making is also debated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in the prevalence of HIV-associated neurocognitive disorder in the USA before (HNRC study, N=678) and after (CHARTER study, N=843) the widespread use of HAART ANI=asymptomatic neurocognitive impairment. MND=mild neurocognitive impairment. HAD=HIV-associated dementia. HAART=highly active antiretroviral therapy
Figure 2
Figure 2
Overview of proposed pathological mechanisms underlying HIV-associated neurocognitive disorders
Figure 3
Figure 3
Summary of the Frascati criteria for HIV-associated neurocognitive disorders
See this image and copyright information in PMC

References

    1. WHO,UNAIDS, UNICEF Global HIV/AIDS response: epidemic update and health sector progress towards universal access. [Oct 12 2012];Progress report 2011. http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf.
    1. Health Protection Agency . HIV in the United Kingdom: 2011 report. Health Protection Services Colindale; London: Nov, 2011. [Dec 30 2012]. http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1317131685847.
    1. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527–35. - PubMed
    1. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699–714. - PubMed
    1. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med. 1987;107:828–36. - PubMed

Publication types

MeSH terms